AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 23.66 |
Market Cap | 1.87B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 1.28 |
PE Ratio (ttm) | 18.8 |
Forward PE | n/a |
Analyst | Hold |
Ask | 28 |
Volume | 558,405 |
Avg. Volume (20D) | 926,778 |
Open | 24.30 |
Previous Close | 23.98 |
Day's Range | 23.80 - 24.31 |
52-Week Range | 22.50 - 32.18 |
Beta | undefined |
About KMT
Kennametal Inc. engages in development and application of tungsten carbides, ceramics, and super-hard materials and solutions for use in metal cutting and extreme wear applications to enable customers work against corrosion and high temperatures conditions worldwide. The company operates through two segments, Metal Cutting and Infrastructure. It offers standard and custom products, including turning, milling, hole making, tooling systems, and ser...
Analyst Forecast
According to 6 analyst ratings, the average rating for KMT stock is "Hold." The 12-month stock price forecast is $27, which is an increase of 12.17% from the latest price.
Next Earnings Release
Analysts project revenue of $488.31M, reflecting a -1.42% YoY shrinking and earnings per share of 0.26, making a -13.33% decrease YoY.
2 months ago · seekingalpha.com
Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy OpportunityPrimary endpoint of pivotal phase 2 study met with statistical significance in using Revumenib for the treatment of relapsed/refractory mNPM1 AML patients; sNDA expected 1st half 2025. PDUFA action da...